The commercial function isn't just marketing. Its critical purpose is to ensure the healthcare delivery system is equipped to receive a new therapy. A great product is merely "table stakes"; adoption hinges on overcoming systemic barriers between regulatory approval and actual patient access.

The launch of Heme Libra, a 28-day hemophilia treatment, revealed a key challenge: patients accustomed to daily infusions were scared to trust the new, infrequent therapy. This shows that marketing truly disruptive products requires building trust and overcoming ingrained user habits, going beyond just demonstrating clinical superiority.

Truly transformative healthcare companies often solve "boring" but fundamental problems. Instead of tackling surface-level symptoms (e.g., appointment booking), the best founders dig deep to fix the complex, underlying infrastructure issues of the healthcare system, creating a durable competitive moat.

While ensuring patient access through co-pay cards and prior authorizations was once the primary focus, it has now become table stakes. Leading pharmaceutical companies are shifting investment toward perfecting the 'day one' experience, recognizing that a poor initial self-administration can lead to immediate therapy abandonment.

Companies excel at tracking post-diagnosis activities like script fills and adherence but often lack insight into the top of the funnel. They don't sufficiently analyze why potential patients delay seeking care, rely on wellness tools, or drop out of the system before ever receiving a diagnosis.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

The biggest competitor for a new technology in pharma quality control isn't another new technology, but established methods. The industry is highly change-averse due to regulatory risk, so any innovation must offer a value proposition that is orders of magnitude better, not just incremental, to overcome this inertia.

Pharmaceutical companies view the healthcare market as a battle for a patient's total spending capacity. They lobby against non-patentable compounds like peptides not because they have a direct competitor, but because every dollar spent on a compounded peptide is a dollar not spent on one of their high-margin, patented prescription drugs, thus protecting their overall revenue.

Over half of all lost deals fail not because a competitor won, but because the customer chose to do nothing. The primary sales challenge is defeating inertia. Buyers, like a group of friends choosing a restaurant, will often default to a familiar, 'good enough' option rather than risk a new, potentially better one. Your solution isn't competing against another product; it's competing against the status quo.